Cargando…
Loading, please waitCargando…
Loading, please waitCondition × Stem Cells
A physician-led look at where mesenchymal stem cell (MSC) therapy stands for Parkinson's disease: what the published clinical evidence actually shows, who qualifies and who does not, and how care is delivered under COFEPRIS regulation at our clinic in Cancún, México. No prices are published online — every case is reviewed in a free medical evaluation, then quoted in writing.
Mesenchymal stem cell (MSC) therapy is an investigational, physician-led adjunct for Parkinson's disease that is being studied for its anti-inflammatory, neurotrophic, and immunomodulatory effects on the diseased dopaminergic system. The strongest human evidence to date is a 2025 Phase 2 randomized trial of allogeneic bone-marrow MSCs reporting motor improvement at the highest dose; it is a promising signal, not a proven disease-modifying therapy. At Regeneris Therapy in Cancún, México, every case begins with a free medical evaluation; only after that do you receive a personalized written quote.
The condition
Parkinson's disease (PD) is a progressive neurodegenerative disorder driven primarily by the loss of dopamine-producing neurons in a brain region called the substantia nigra. As those neurons die, the basal-ganglia circuitry that normally smooths movement becomes dysregulated, producing the motor features that define the diagnosis and, over time, a wide range of non-motor symptoms that affect mood, sleep, autonomic function, and cognition.
What the research shows
Peer-reviewed clinical evidence for MSC therapy in Parkinson's disease is emerging and increasingly serious, but it does not yet meet the bar of an established disease-modifying treatment. The strongest source today is a 2025 Phase 2 randomized, placebo-controlled trial in mild-to-moderate PD. It sits in a wider body of mechanistic, preclinical, and earlier-phase clinical literature that supports a biologically rational role for MSCs as an anti-inflammatory and neurotrophic intervention — without yet proving they slow neurodegeneration in humans. The notes below summarize the citations we rely on and what each does and does not show. None of it guarantees an individual outcome.
A randomized, placebo-controlled Phase 2 trial in patients with mild-to-moderate idiopathic Parkinson's disease evaluated allogeneic bone-marrow-derived mesenchymal stem cells delivered as intravenous infusions. The three-infusion group reported a meaningful improvement on the MDS-UPDRS Part III motor scale, and the regimen was generally well tolerated. The authors frame the results as a positive efficacy signal that justifies further investigation — not as definitive proof of disease modification — and explicitly call for larger trials to confirm dosing, durability, and effect on disease progression.
Candidacy
MSC therapy for Parkinson's disease is not a first-line treatment, and it is not appropriate for every patient. The lists below describe the general clinical factors that point toward or away from regenerative care for this condition at our clinic in Cancún, México. None of these supersede a physician evaluation — they orient you before one. Patients with PD always remain under the care of their treating neurologist; MSC therapy is considered only as a possible adjunct.
Regulation & location
Regeneris Therapy operates as a physician-led regenerative-medicine clinic in Cancún, Quintana Roo, México, under COFEPRIS — México's federal health authority, the regulatory equivalent of the U.S. FDA. That framework defines who may prescribe and deliver stem cell therapy, where cells may be processed, and what advertising claims a clinic may publish. For a serious YMYL indication like Parkinson's disease, this regulatory anchor matters as much as any single protocol.
Our clinic operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, the federal records that authorize medical operations and regulate any advertising of regenerative therapies in México.
How we work
Our model is intentionally medical, not transactional. We do not publish prices online for stem cell therapy, and we do not sell a fixed package. Every Parkinson's case starts with a structured physician evaluation and ends with a written plan and a personalized quote — so you can make an informed decision, with your neurologist's input, before committing.
Share your neurologist's reports, recent imaging, current medications, comorbidities, and goals. A Regeneris physician reviews your case — by message or video first if you are traveling from outside Cancún — and answers honestly whether MSC therapy is even worth considering as an adjunct for your specific Parkinson's picture.
We expect you to remain under the care of your treating neurologist. If MSC therapy may be appropriate, we communicate openly with that physician about your existing plan, any medication considerations, and how follow-up will be shared. We will not pressure you to stop established PD medications.
If MSC therapy is reasonable to consider, you receive a written plan describing cell source, route of administration (typically intravenous infusion for a neurological indication), number of sessions, follow-up schedule, and the personalized quote — clearly stated, no surprises. You take the document home and decide on your own time.
Honest expectations
We treat this section as the most important on the page. Marketing language in regenerative medicine has historically run ahead of the evidence, and Parkinson's disease is a particularly sensitive YMYL space because patients and families are understandably hopeful. We are deliberately conservative because honesty is the only defensible position.
FAQ
The questions patients and families ask us most when considering MSC therapy for Parkinson's disease at our clinic in Cancún, México.
No — and any clinic that says otherwise is overstating the evidence. Parkinson's disease is a progressive neurodegenerative condition, and current MSC therapy is investigational. The strongest human study to date is the 2025 Phase 2 randomized trial by Schiess and colleagues, which reported a positive motor signal at the highest dose of allogeneic bone-marrow MSCs but was explicitly framed by its authors as a basis for further investigation, not as definitive proof of disease modification. We do not use the word 'cure' and will not promise one. MSC therapy at Regeneris is considered, when appropriate, as a physician-supervised adjunct to your neurologist's care — never a replacement for it.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for Parkinson's disease is investigational and is not a substitute for standard neurology care; outcomes vary by patient, disease stage, and protocol, and no individual response is guaranteed. The decision to pursue MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician and ongoing coordination with your treating neurologist; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, your neurologist's recent reports, and any imaging. A Regeneris physician will review your case from Cancún, México and tell you — honestly — whether MSC therapy is worth considering as an adjunct, what protocol may fit, and what the personalized written quote would look like after your free medical evaluation.
A peer-reviewed mechanistic review describes why MSCs are biologically plausible as a disease-modifying tool in PD: they secrete neurotrophic factors (including BDNF), produce anti-inflammatory cytokines such as IL-10 and TGF-β, can differentiate toward neural lineages including dopaminergic precursors, and may transfer mitochondria and enhance autophagy in stressed neurons. The authors are explicit that these are pathways supported by mechanistic and preclinical data — not yet by definitive human trials — and frame MSCs as an investigational, multitarget candidate rather than an established therapy.
Mechanistic context that frames the Parkinson's literature. The field's founding figure reframed MSCs as 'medicinal signaling cells,' arguing that their therapeutic benefit comes chiefly from secreted, paracrine factors — exosomes, growth factors, cytokines — rather than from engraftment and tissue replacement. In a neurodegenerative context, this means MSCs are best understood as a way to modulate the diseased microenvironment around remaining dopaminergic neurons, not as a literal source of replacement neurons.
A focused review of the rationale for MSC-based therapy in Parkinson's disease, summarizing the trophic, paracrine, and differentiation properties that make MSCs an attractive candidate over ethically and immunologically more complex sources such as embryonic stem cells. The authors note both the promise — MSCs can be induced toward dopaminergic phenotypes and can produce neurotrophic substances — and the limits — most evidence is preclinical and the field still needs robust controlled trials before MSCs can be considered an established PD therapy.
Read together, the literature supports a careful, conservative position: MSC therapy is biologically rational for Parkinson's disease and now has a positive Phase 2 efficacy signal, but it remains investigational and is not a substitute for standard neurology care. Whether it is reasonable to consider for your specific case is a medical question — confirmed only in evaluation, never assumed from a search query.
Cells used in our protocols are expanded under sterile, COFEPRIS-certified laboratory conditions with donor screening and quality-control testing — a baseline patients and families should expect from any serious clinic, especially for a neurological indication.
Every protocol is prescribed and supervised by a licensed Mexican physician at our clinic in Cancún, México. Care is not delegated to non-physician staff, decisions are documented in your written plan, and we expect — not just allow — coordination with your treating neurologist.
Patients traveling to Cancún, México from the United States, Canada, or elsewhere often combine evaluation, treatment, and rest on a single short itinerary; our team helps coordinate the medical side from your first message.
If you proceed, treatment is delivered at our clinic in Cancún, México under physician supervision, with structured follow-up that respects your neurologist's ongoing role. We reassess outcomes honestly — including saying so plainly if response is modest or absent — and never claim to have cured the disease.
This is the same workflow whether you are a Cancún resident, a Mexican patient from another state, or an international patient flying in: free evaluation first, neurologist in the loop, written quote only after we understand your case.
No. We expect you to remain under the care of your treating neurologist and to continue your prescribed medications (levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, and so on) unless that neurologist directs otherwise. A serious regenerative-medicine clinic does not ask Parkinson's patients to abandon established therapy in exchange for an investigational adjunct, and we will not. Our role is to coordinate openly with your neurology team, not to compete with it.
For Parkinson's disease, the route most studied in recent clinical trials — including the 2025 Phase 2 trial — is intravenous infusion of mesenchymal stem cells, typically given as multiple sessions spaced over weeks to months under physician supervision. The exact protocol — cell source, number of infusions, interval, and follow-up cadence — is individualized in your written plan after evaluation. We do not commit to a route or schedule on a webpage; we commit to it on paper, after we understand your case.
Onset is gradual, not immediate. Anti-inflammatory and neurotrophic effects, when they occur, build over weeks to months rather than days. Recent trials have used several months of follow-up to assess motor and quality-of-life outcomes, and we schedule structured follow-up in collaboration with your neurologist over that kind of window. Some patients describe modest improvements in motor symptoms, energy, or sleep; others see little change. We commit to honest reassessment either way.
In recent published trials of allogeneic MSC therapy for Parkinson's disease, the infusions were generally well tolerated and no major treatment-related safety concerns were reported in small samples. Common risks of any intravenous infusion — temporary soreness, transient flu-like symptoms, low risk of infection — are reviewed with you in your evaluation. Patients with active malignancy, active infection, pregnancy, uncontrolled immunosuppression, advanced Parkinson-plus syndromes, severe cognitive impairment, or unstable cardiopulmonary disease are generally not appropriate candidates without specialist coordination.
Regeneris does not publish prices online for stem cell therapy. Our model is intentional: free medical evaluation first, then a written plan and a personalized quote that reflect your specific Parkinson's picture, current medications, imaging, and goals. We chose this approach because medicine — especially for a serious neurological condition — is not a catalog purchase, and a number on a homepage cannot fairly represent the decision you and your family are making. Your full quote is delivered in writing after evaluation, with no obligation to proceed.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How COFEPRIS regulates regenerative medicine in México, what donor screening looks like, and how to evaluate any clinic claim.